Abstract
The first study on fatty acid composition of the postmortem brains of patients with psychiatric disorders was performed by Horrobin et al. in 1991, who found abnormalities in polyunsaturated fatty acids (PUFAs) in patients with schizophrenia. About a decade later, research in this field was re-started by Yao et al., followed by a number of other research groups. The results seem to show that the PUFA changes in psychiatric disorders may be specific to certain brain regions, but the underlying mechanisms remain unclear. Here we review these case-control studies of postmortem brain composition.
Keywords: polyunsaturated fatty acids, case-control study, schizophrenia, bipolar disorder, major depressive disorder, postmortem brain
Current Psychopharmacology
Title:Polyunsaturated Fatty Acids and their Related Enzymes in Postmortem Brain Tissues of Patients with Psychiatric Disorders
Volume: 2
Author(s): Kei Hamazaki, Tomohito Hamazaki and Hidekuni Inadera
Affiliation:
Keywords: polyunsaturated fatty acids, case-control study, schizophrenia, bipolar disorder, major depressive disorder, postmortem brain
Abstract: The first study on fatty acid composition of the postmortem brains of patients with psychiatric disorders was performed by Horrobin et al. in 1991, who found abnormalities in polyunsaturated fatty acids (PUFAs) in patients with schizophrenia. About a decade later, research in this field was re-started by Yao et al., followed by a number of other research groups. The results seem to show that the PUFA changes in psychiatric disorders may be specific to certain brain regions, but the underlying mechanisms remain unclear. Here we review these case-control studies of postmortem brain composition.
Export Options
About this article
Cite this article as:
Hamazaki Kei, Hamazaki Tomohito and Inadera Hidekuni, Polyunsaturated Fatty Acids and their Related Enzymes in Postmortem Brain Tissues of Patients with Psychiatric Disorders, Current Psychopharmacology 2013; 2 (1) . https://dx.doi.org/10.2174/2211556011302010066
DOI https://dx.doi.org/10.2174/2211556011302010066 |
Print ISSN 2211-5560 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-5579 |
Call for Papers in Thematic Issues
Breakthroughs in drug design, development and delivery system for the management of neuro-psychiatric disorders
Neuropsychiatric diseases are one of the main causes of disability, affecting millions of people. Various drugs are used for its treatment, although no effective therapy has been found yet. The blood brain barrier (BBB) significantly complicates drugs delivery to the target cells in the brain tissues. This proposal describes the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Surface Modification of Nanocarriers for Cancer Therapy
Current Nanoscience Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery Extracellular Citrate in Health and Disease
Current Molecular Medicine Diverse Models for the Prediction of Dual mTOR and PI3Kα Inhibitory Activities of Substituted 4-morpholinopyrrolopyrimidines
Letters in Drug Design & Discovery Modulation of MicroRNAs by <i>Euphorbia Microsciadia</i> Boiss in MDA-MB-231 Cell Line: New Possibilities in Breast Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Anticancer Natural Products with Collateral Sensitivity: A Review
Mini-Reviews in Medicinal Chemistry Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry Potential Utilization of Bystander / Abscopal-Mediated Signal Transduction Events in the Treatment of Solid Tumors
Current Signal Transduction Therapy Proteomic Analysis of Glioma Chemoresistance
Current Neuropharmacology Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research Autologous Formalin-Fixed Tumor Vaccine
Current Pharmaceutical Design Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging
Current Protein & Peptide Science A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry To Die or Not to Die: That is the Autophagic Question
Current Molecular Medicine Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Metal Oxide Nanomaterials in Nanomedicine: Applications in Photodynamic Therapy and Potential Toxicity
Current Topics in Medicinal Chemistry Anticancer Mechanisms of Berberine: A Good Choice for Glioblastoma Multiforme Therapy
Current Medicinal Chemistry